|
JP2019135244A
|
|
2-[5-[n-(4-fluorophenyl)carbamoyl]pyrimidine-2-ilsulfanylmethyl]-4-(trifluoromethoxy)phenyl boronic acid
|
|
US2020297661A1
|
|
Treating pain using desmetramadol
|
|
WO2019165315A1
|
|
Method for treating cancer using chemokine antagonists alone or in combination
|
|
US2018296580A1
|
|
Method for treating cancer using dual antagonists of CXCR1 and CXCR2
|
|
US2018177808A1
|
|
Method for treating cancer using chemokine antagonists
|
|
US2017128474A1
|
|
Method for treating cancer using chemokine antagonists
|
|
US2015038461A1
|
|
Thiopyrimidinecarboxamides as CXCR1/2 modulators
|
|
CA2920172A1
|
|
2- [5- [n- (4-fluorophenyl) carbamoyl] pyrimidin-2-ylsulfanylmethyl] -4- (trifluoromethoxy) phenyl] boronic acid
|
|
US2014171436A1
|
|
Treatment of antifolate neurotoxicity
|
|
RS56570B1
|
|
Compositions and methods for overcoming resistance to tramadol
|
|
CA2811990A1
|
|
Aminopyridine- and aminopyrimidinecarboxamides as cxcr2 modulators
|
|
EP2942346A1
|
|
Pyridinecarboxamides as cxcr2 modulators
|
|
WO2010085717A1
|
|
Pharmaceutical composition comprising racemic aminopterin
|
|
US2010020299A1
|
|
Instrumentation and method for maskless photolithography
|
|
US2008269065A1
|
|
Conformationally Constrained Analytical Probes
|
|
US2006205729A1
|
|
Aminopterin dosage forms and methods for inflammatory disorders
|
|
US2005209239A1
|
|
Compositions and methods employing aminopterin
|
